

9-27-02

TECH CENTER 1600/2900

1615  
OCT 01 2002

RECEIVED

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0034

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/897,801
Filing Date	June 29, 2001
First Named Inventor	Pinkerton
Group Art Unit	1615
Examiner Name	Azpuru
Attorney Docket Number	6794S-000019/US

Total Number of Pages in This Submission

2

**ENCLOSURES (check all that apply)**

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment / Response<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)<br><input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br><p style="text-align: center;"><b>Response to Restriction/<br/>Election Requirement</b></p> |
|---|---|--|

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
or  
Individual name

Donald R. Holland, Reg. No. 35,197

Signature

Date

September 26, 2002

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: September 26, 2002

Typed or printed name

Donald R. Holland, 35,197

Signature

Date

September 26, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Express Mail No. EV196263785US**



EV196263785US

PATENT  
Attorney Docket No. 6794S-000019

TECH CENTER 1600/2900

OCT 01 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pinkerton

Serial No.: 09/897,801

Filed: June 29, 2001

For: ENHANCED PHARMACOKINETIC  
PROFILE OF INTRADERMALLY  
DELIVERED SUBSTANCES

Art Unit: 1615

Examiner: C. Azpuru

13/Election  
+C

Commissioner for Patents  
Washington, D.C. 20231

Be  
10-4-02


RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

This paper is submitted in response to Restriction/Election Requirement of September 24, 2002 and subsequent interview with Examiner on September 26, 2002. In the interview, restriction was required between Group 1, Claims 85-116 and 199-138 to a method of delivering intradermally and Group 2 Claims 117 and 118 to a device for delivering intradermally. Applicant elects Group 1 Claims 85-116 and 199-138 for further prosecution without traverse.

In addition, Applicant cancels Claim 23 without prejudice or disclaimer.

Should any questions arise, the Patent and Trademark Office is requested to contact the undersigned attorney.

Respectfully submitted,

  
Donald R. Holland Reg. No. 35197  
HARNESS, DICKEY & PIERCE, P.L.C.  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500